|
FI109453B
(fi)
|
1999-06-30 |
2002-08-15 |
Orion Yhtymae Oyj |
Farmaseuttinen koostumus
|
|
US20040166159A1
(en)
*
|
2002-05-29 |
2004-08-26 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
|
|
US20050147670A1
(en)
*
|
2002-05-29 |
2005-07-07 |
Impax Laboratories Inc. |
Oral disintegrating dosage forms
|
|
US7094427B2
(en)
*
|
2002-05-29 |
2006-08-22 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US20030224045A1
(en)
*
|
2002-05-29 |
2003-12-04 |
Chien-Hsuan Han |
Combination immediate release sustained release levodopa/carbidopa dosage forms
|
|
US20040006072A1
(en)
*
|
2002-06-25 |
2004-01-08 |
Franz Robert M. |
Sustained-release alprazolam composition
|
|
KR20050083750A
(ko)
*
|
2002-10-11 |
2005-08-26 |
디포메드 디벨롭먼트 리미티드 |
위-체류성 레보도파 전달 형태
|
|
AR044007A1
(es)
|
2003-04-11 |
2005-08-24 |
Newron Pharmaceuticals Inc |
Metodos para el tratamiento de la enfermedad de parkinson
|
|
EP1588704A1
(en)
|
2004-04-22 |
2005-10-26 |
Newron Pharmaceuticals S.p.A. |
Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
|
|
SE0401842D0
(sv)
|
2004-07-12 |
2004-07-12 |
Dizlin Medical Design Ab |
Infusion and injection solution of levodopa
|
|
WO2006037061A2
(en)
*
|
2004-09-28 |
2006-04-06 |
Farouk Karoum |
Compositions and methods of using d-dopa to treat parkinson's disease
|
|
US20060173074A1
(en)
|
2004-11-10 |
2006-08-03 |
Juha Ellmen |
Treatment of restless legs syndrome
|
|
PL1896006T3
(pl)
*
|
2005-06-08 |
2010-03-31 |
Orion Corp |
Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
|
|
AU2012216377C1
(en)
*
|
2005-06-08 |
2013-10-10 |
Orion Corporation |
Oral dosage form
|
|
CA2613631A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Improved dosage forms for movement disorder treatment
|
|
MY148644A
(en)
|
2005-07-18 |
2013-05-15 |
Orion Corp |
New pharmaceutical compounds
|
|
PL1907382T3
(pl)
*
|
2005-07-26 |
2016-01-29 |
Bial Portela & Ca Sa |
Pochodne nitrokatecholowe jako inhibitory COMT
|
|
WO2007016190A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Duke University |
Antiparkinsonian action of phenylisopropylamines
|
|
WO2007034024A2
(en)
*
|
2005-09-21 |
2007-03-29 |
Orion Corporation |
Treatment of symptoms of parkinson' s disease
|
|
WO2007056570A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Teva Pharmaceutical Industries Ltd. |
Levodopa compositions
|
|
WO2007069274A2
(en)
*
|
2005-11-09 |
2007-06-21 |
Torrent Pharmaceuticals Limited |
Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
|
|
GB2429645A
(en)
*
|
2006-03-10 |
2007-03-07 |
Sekhsaria Chemicals Ltd |
Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
|
|
CN100384411C
(zh)
*
|
2006-03-17 |
2008-04-30 |
北京科信必成医药科技发展有限公司 |
卡左双多巴口腔崩解片
|
|
WO2007113371A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Iprbox Oy |
Pharmaceutical composition and preparation method thereof
|
|
EP1845097A1
(en)
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
EP1870097A1
(en)
*
|
2006-06-15 |
2007-12-26 |
Newron Pharmaceuticals S.p.A. |
Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
|
|
US8106056B2
(en)
*
|
2006-06-16 |
2012-01-31 |
Solvay Pharmaceuticals B.V. |
Combination preparations comprising bifeprunox and a dopamine agonist
|
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
|
US8741342B2
(en)
*
|
2006-10-30 |
2014-06-03 |
Wockhardt Research Centre |
Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
|
|
AU2007338631A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
|
EP2114374A4
(en)
*
|
2006-12-27 |
2011-03-23 |
Wockhardt Research Center |
PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
|
|
EP1946756A1
(en)
*
|
2007-01-17 |
2008-07-23 |
Revotar Biopharmaceuticals AG |
Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
|
|
BRPI0721213B1
(pt)
|
2007-01-31 |
2021-11-09 |
Bial - Portela & Ca, S.A. |
Uso de nitrocatecóis substituídos, e embalagem
|
|
US20110171275A1
(en)
*
|
2007-08-20 |
2011-07-14 |
Team Academy Of Pharmaceutical Science |
Gastroretentive drug delivery system, preparation method and use thereof
|
|
EP2252284B1
(en)
*
|
2008-02-06 |
2011-05-25 |
Wockhardt Research Centre |
Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
|
|
MX2010008707A
(es)
*
|
2008-02-06 |
2011-03-25 |
Wockhardt Ltd |
Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
|
|
WO2009116882A1
(en)
|
2008-03-17 |
2009-09-24 |
Portela & Ca., S.A. |
Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
|
|
UA102111C2
(uk)
|
2008-08-22 |
2013-06-10 |
Вокхардт Рісерч Сентер |
Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
|
|
CA2734972C
(en)
*
|
2008-08-22 |
2017-03-28 |
Wockhardt Research Centre |
An extended release pharmaceutical composition of entacapone or salts thereof
|
|
TR200806646A2
(tr)
*
|
2008-09-03 |
2009-06-22 |
Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. |
Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
|
|
EP2233131A1
(en)
|
2009-03-23 |
2010-09-29 |
Laboratorios Lesvi, S.L. |
Pharmaceutical composition containing levodopa, entacapone and carbidopa
|
|
PT2413912T
(pt)
|
2009-04-01 |
2019-06-11 |
Bial Portela & Ca Sa |
Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
|
|
PL2432454T3
(pl)
*
|
2009-05-19 |
2017-10-31 |
Neuroderm Ltd |
Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
|
|
US9750702B2
(en)
|
2009-12-25 |
2017-09-05 |
Innopharmax, Inc. |
Pharmaceutical composition for treating parkinson's disease and preparation method thereof
|
|
EA026419B1
(ru)
|
2010-03-04 |
2017-04-28 |
Орион Корпорейшн |
Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
|
|
DE102010023828A1
(de)
|
2010-06-15 |
2011-12-15 |
IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH |
Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
|
|
PT2640358T
(pt)
*
|
2010-11-15 |
2018-02-23 |
Neuroderm Ltd |
Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
EP2508174A1
(en)
|
2011-04-06 |
2012-10-10 |
Ljiljana Sovic Brkicic |
Pharmaceutical composition
|
|
WO2012147099A1
(en)
|
2011-04-25 |
2012-11-01 |
Suven Nishtaa Pharma Pvt. Ltd. |
Pharmaceutical compositions of levodopa, carbidopa and entacapone
|
|
CA2833443C
(en)
*
|
2011-04-26 |
2017-11-07 |
Innopharmax, Inc. |
A composition of entacapone
|
|
JP6456143B2
(ja)
|
2011-12-13 |
2019-01-23 |
ノヴィファーマ，エス．アー． |
カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
|
|
TR201204839A2
(tr)
*
|
2012-04-25 |
2012-12-21 |
Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. |
Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
|
|
NZ703341A
(en)
|
2012-06-05 |
2016-11-25 |
Neuroderm Ltd |
Compositions comprising apomorphine and organic acids and uses thereof
|
|
AU2014229127B2
(en)
*
|
2013-03-13 |
2018-04-05 |
Neuroderm Ltd |
Method for treatment of parkinson's disease
|
|
EP2799065A1
(en)
*
|
2013-04-30 |
2014-11-05 |
Deva Holding Anonim Sirketi |
Levodopa carbidopa entacapone pharmaceutical formulations
|
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
|
CN105658211A
(zh)
|
2013-10-07 |
2016-06-08 |
怡百克制药公司 |
左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
DK3116475T3
(da)
|
2014-03-13 |
2020-12-07 |
Neuroderm Ltd |
Dopa-decarboxylasehæmmersammensætninger
|
|
JP6622310B2
(ja)
|
2014-09-04 |
2019-12-18 |
ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ |
レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
|
|
RU2017120184A
(ru)
|
2014-11-28 |
2018-12-28 |
БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. |
Лекарства для замедления течения болезни паркинсона
|
|
WO2016101969A1
(en)
|
2014-12-23 |
2016-06-30 |
Pharmathen S.A. |
Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
|
|
US10555922B2
(en)
|
2015-09-04 |
2020-02-11 |
Lobsor Pharmaceuticals Aktiebolag |
Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
|
|
AU2017297718B2
(en)
*
|
2016-07-11 |
2023-06-08 |
Contera Pharma A/S |
Pulsatile drug delivery system for treating morning akinesia
|
|
EP3500246B1
(en)
|
2016-08-18 |
2021-08-04 |
Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Antiparkinson tablet formulation with improved dissolution profile
|
|
WO2019145773A1
(en)
|
2017-12-15 |
2019-08-01 |
Nos Life Sciences Corporation |
Liposomal-encapsulated formulations
|
|
EP3768263B1
(en)
|
2018-03-23 |
2025-10-29 |
LobSor Pharmaceuticals Aktiebolag |
Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
KR20230124622A
(ko)
|
2020-12-22 |
2023-08-25 |
암닐 파마슈티컬스 엘엘씨 |
레보도파 투여 요법
|
|
US12161612B2
(en)
|
2023-04-14 |
2024-12-10 |
Neuroderm, Ltd. |
Methods and compositions for reducing symptoms of Parkinson's disease
|